stockrowHalozyme Therapeutics, Inc.
HALO Healthcare Biotechnology
Halozyme Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 37.6% from fiscal 2024.
- Revenue
- +39.2%
- EPS
- +45.6%
- Free cash flow
- −58.6%
- Total debt
- +115.1%
Quarter to September 2026, against a year earlier
Follow HALO
Alert me
Halozyme Therapeutics, Inc. (HALO) Debt to equity
Halozyme Therapeutics, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was −58.8×, down 103× from fiscal 2025 (43.9×). Over the past ten years it has ranged from −6.7× (fiscal 2016) to 43.9× (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.0× and below the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | 43.9× | 960.54% |
| FY2024 | 4.1× | (76.86%) |
| FY2023 | 17.9× | 101.68% |
| FY2022 | 8.9× | 99.27% |
| FY2021 | 4.5× | 69.26% |
| FY2020 | 2.6× | (40.06%) |
| FY2019 | 4.4× | 763.96% |
| FY2018 | 0.5× | (47.71%) |
| FY2017 | 1.0× | — |
| FY2016 | −6.7× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Sep 2026 | −58.8× | — |
| Jun 2026 | 15.0× | 53.15% |
| Mar 2026 | 9.8× | (77.75%) |
| Dec 2025 | 43.9× | 1,364.10% |
| 43 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. | −58.8× |
| BBIO BridgeBio Pharma, Inc. compare | −1.2× |
| EXEL Exelixis, Inc. compare | 0.0× |
| SMMT Summit Therapeutics PLC compare | 0.0× |
| KYMR Kymera Therapeutics, Inc. compare | 0.0× |
| TECH Bio-Techne Corp compare | 0.1× |
| ASND Ascendis Pharma A/S compare | 0.3× |
| BMRN BioMarin Pharmaceutical Inc. compare | 0.7× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.3× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on HALO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement